Author details

Full Name

Analisa DiFeo

Affiliation

ORCID

Career Start Year

2003

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36788429	Small-Molecule-Mediated Stabilization of PP2A Modulates the Homologous Recombination Pathway and Potentiates DNA Damage-Induced Cell Death.	Mol Cancer Ther	2023
37932806	MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer.		2023
36909636	The nutritional supplement taurine activates p53-dependent and independent tumor suppressor mechanisms in various cellular models of ovarian cancer.		2023
34921012	Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.	Cancer Res	2022
36131208	Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.	Nature Metabolism	2022
34138519	STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?	J Pathol Clin Res	2021
33574092	The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.	Cancer Research	2021
33513911	Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts.	Diagnostics	2021
33776708	Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series.	Case Rep Oncol	2021
31541192	Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.	Oncogene	2020
32591511	miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling.	Nat Commun	2020
33027304	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.	PLoS One	2020
33322239	The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.	International Journal of Molecular Sciences	2020
31358529	Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.	Cancer Res	2019
30629937	A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs.	Stem Cell Reports	2019
29848180	Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines.	Reproductive Sciences	2019
31142515	The Highly Recurrent PP2A AÎ±-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.	Cancer Res	2019
31164413	The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.	Mol Cancer Res	2019
30896539	Repurposed Drugs Trials for Ovarian Cancer.	Cancer journal (Sudbury, Mass.)	2019
30670712	miR-181a modulates circadian rhythm in immortalized bone marrow and adipose derived stromal cells and promotes differentiation through the regulation of PER3.	Scientific Reports	2019
29634688	Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.	Nat Med	2018
28967908	Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.	Oncogene	2018
30301560	Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.	Gynecologic Oncology	2018
30206106	Sprague Dawley <i>Rag2</i>-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.	Mol Cancer Ther	2018
29358171	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.	Cancer Res	2018
29653924	Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.	Clinical Cancer Research	2018
29334376	Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.	Nat Med	2018
27819677	InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.	Oncogene	2017
28504649	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.	J Clin Invest	2017
28838952	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.	Journal of Experimental Medicine	2017
26234677	RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression.	Oncogene	2016
27194815	A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.	Annals of Oncology	2016
27105520	Cisplatin induces stemness in ovarian cancer.	Oncotarget	2016
27191653	Altered glutamine metabolism in platinum resistant ovarian cancer.	Oncotarget	2016
26782955	Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.	Annals of Oncology	2016
26125441	Critical role of Wnt/Î²-catenin signaling in driving epithelial ovarian cancer platinum resistance.	Oncotarget	2015
25731210	miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.	Biomarkers in Medicine	2015
24522433	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.	J Invest Dermatol	2014
24394555	microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.	Nat Commun	2014
24297540	Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance.	Pac Symp Biocomput	2014
24465580	Crowdsourcing awareness: exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk.	PLoS One	2014
23372829	Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.	PLoS ONE	2013
22806255	A new feature of the MYH9-related syndrome: chronic transaminase elevation.	Hepatology	2013
23345610	KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.	Sci Transl Med	2013
22277651	Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene.	J Biol Chem	2012
22653055	Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.	J Clin Invest	2012
22123909	Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity.	Blood	2011
21083612	The first report of homozygous May-Hegglin anomaly E1841K mutation.	European Journal of Haematology	2011
20563750	Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression.	Dig Dis Sci	2011
20844588	Nucleo-cytoplasmic localization domains regulate KrÃ¼ppel-like factor 6 (KLF6) protein stability and tumor suppressor function.	PLoS ONE	2010